Toggle Side Panel

Therapy for people with a rare form of blood cancer

max
MariaPCC 29 October 2024

Just over 700 people in England are eligible to benefit from elranatamab for multiple myeloma that has returned and stopped responding to previous treatments, and who have had at least three lines of other kinds of treatment and whose cancer has worsened since receiving the last treatment. Elranatamab, also known as Elrexfio and made by Pfizer, is recommended in final draft guidance from the National Institute for Health and Care Excellence for use via the Cancer Drugs Fund while more evidence is collected about its effectiveness.

Categories: News

Report

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .
Keep up to date

Sign up to receive our daily news alerts straight to your inbox. Subscribe to our weekly newsletter containing a summary of the week’s news, blog and vote on our poll.

Weekly Newsletter

Daily news updates

Have a discussion

Help keep the conversation going between meetings by creating a forum to hold discussions with your members. It’s an easy way to manage and communicate with members.

Create a network

Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.

Networks can be open to all or available only to a closed group defined by the administrator.

Join or create a network here.